Otezla patent expiry?

Otezla (apremilast) patent status

Otezla is the brand name for the phosphodiesterase‑4 inhibitor apremilast.
The U.S. patents that cover the drug’s active ingredient and its formulation are the most relevant for determining when the drug can become generic‑eligible. The key U.S. patents that are currently in force for apremilast (or that have already expired) are:

Bottom line

• The core composition‑of‑matter patents that cover apremilast itself expire in March 2026 (US 7,991,004).
• The method‑of‑use and formulation patents that cover the drug’s specific indications and tablet format expire in June 2026 (US 2012/0134112) and October 2027 (US 2014/0254878, 2014/0305959, 2014/0305972).

Implications for generics

In the U.S., a generic manufacturer can file an ANDA (Abbreviated New Drug Application) to seek approval once all the patents that cover the drug’s active ingredient, method of use, and formulation have expired. Based on the dates above, the earliest a generic could potentially enter the market would be after October 2027—provided no secondary patents or litigation keep the market closed.

Caveats

• Patent extensions: The original patents (especially composition‑of‑matter) could receive a 5‑year extension under the Hatch‑Waxman Act, which would push the expiration dates by up to five years.
• Secondary patents: New patents covering improved formulations, delivery systems, or combination products may extend exclusivity beyond the primary patents listed above.
• Litigation: Patent disputes (e.g., “patent‑trolling” challenges) can delay generic entry even after the primary patents expire.
• International differences: Patent expiration dates vary by country. The dates above are specific to the United States.

If you’re a prescriber or patient, the best source for the most up‑to‑date information is the FDA’s Orange Book, which lists all patents and exclusivities for approved drugs. You can look up “apremilast” (Otezla) there for the exact filing numbers and expiration dates in your jurisdiction.